Laboratory Testing for HER2/neu in Breast Carcinoma: An Evolving Strategy to Predict Response to Targeted Therapy

Nils M. Diaz, MD, Interdisciplinary Oncology Program at the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, Tampa, Florida. Submitted July 1, 2001; accepted August 9, 2001

Cancer Control. 2001;8(5) 

In This Article

An Evolving Strategy for Determining HER2/neu Status

A consensus is evolving that a useful strategy for determining whether anti-HER2/neu therapy should be offered to a patient in appropriate clinical circumstances include both IHC and FISH analysis. Such a strategy will require modification according to which laboratory testing methods best predict response to available and future anti-HER2/neu-directed therapies. Specifically, IHC should presently be used as a screen for overexpression of the oncoprotein based on the following factors: (1) IHC is less expensive, more routine in clinical laboratories, and less labor intensive than FISH, (2) IHC has a high concordance with FISH when the result is negative (0 or 1+) or strongly positive (3+), and (3) studies have, as yet, not shown that nonoverexpressors -- 0 or 1+ by IHC but FISH-positive -- benefit from targeted therapy. If the IHC result is weakly positive or indeterminate (2+), testing the carcinoma by FISH for gene amplification is recommended to help in selecting patients for the anti-HER2/neu therapy trastuzumab.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: